Ximena Hernández-Ramos

Ms. Ximena Hernández-Ramos


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2026 in Molecules
Verified
Journal Article
Open access
PDF file
MDMayra Xochitl Durán-Maldonado
Mayra Xochitl Durán-Maldonado
XHXimena Hernández-Ramos
Ximena Hernández-Ramos
MMMarlene Estefania Campos Morales
Marlene Estefania Campos Morales
MMMartinez-Alcantar Martinez-Alcantar
Martinez-Alcantar Martinez-Alcantar
LPLaura Hernández Padilla
Laura Hernández Padilla
Jesús Campos-GarcíaJesús Campos-García
Jesús Campos-García
Triple-negative breast cancer (TNBC) is a highly aggressive subtype linked to a high rate of metastasis and low survival rates worldwide. Bacterial cyclodipeptides (CDPs) demonstrate anticancer properties by targeting multiple signaling pathways. The impact of CDPs on TNBC metastasis was evaluated both in vitro and in advanced-stage tumors in immunosuppressed female mice. CDPs significantly decreased the migratory and invasive capabilities of the MDA-MB-231 cell line, outperforming methotrexate (MTX). This effect was associated with the inhibition of Akt/mTOR/S6K phosphorylation, as well as Gab1, Vimentin, and FOXO1. Mice bearing MDA-MB-231 xenografts treated with CDPs alone or in combination with MTX showed near-complete suppression of primary tumors and metastatic sites in organs; notably, the combined treatment displayed a synergistic effect. Consequently, key proteins involved in tumor progression and metastasis, including p-Akt, p-Gab1, and FOXO1, were markedly inhibited in tumors from CDP-treated mice. Additionally, genes related to EMT, invasiveness, and immune modulation—including PTEN, SNAIL, CXCL1, BRCA1, GADD45A, and PD-L1—were dysregulated in the livers of TNBC-bearing mice; however, CDP treatment restored their expression more effectively than MTX. These findings suggest that the anti-metastatic effects of CDPs in the TNBC xenograft model involve modulation of the Akt/mTOR/S6K pathway, EMT, invasiveness, and immune modulation, highlighting their potential for further preclinical development.

19 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MDMayra Xochitl Durán-Maldonado
Mayra Xochitl Durán-Maldonado
MMMarlene Estefania Campos Morales
Marlene Estefania Campos Morales
MMMartinez-Alcantar Martinez-Alcantar
Martinez-Alcantar Martinez-Alcantar
LPLaura Hernández Padilla
Laura Hernández Padilla
Jesús Campos-GarcíaJesús Campos-García
Jesús Campos-García
XHXimena Hernández-Ramos
Ximena Hernández-Ramos
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype associated with a high metastatic rate and low survival worldwide. Bacterial cyclodipeptides (CDPs) exhibit anticancer properties by targeting multiple signaling pathways. Methods: The effect of CDPs on the metastasis of the TNBC MDA-MB-231 cell line was evaluated both in vitro and in advanced-stage tumors in immunosuppressed female mice. Results: CDPs more effectively reduced the migratory and invasive abilities of the MDA-MB-231 cell line than methotrexate (MTX). The anti-metastatic effect correlated with inhibition of the Akt/mTOR/S6K pathway, evidenced by decreased expression of markers such as Gab1, Vimentin, and FOXO1. Mice with MDA-MB-231 xenografts treated with CDPs, alone or in combination with MTX, showed near-complete suppression of primary tumor growth and metastatic foci in tumor and organ tissues. Key proteins involved in signaling pathways associated with tumor progression and metastasis such as p-Akt, p-Gab1, and FOXO1 were markedly reduced expression in tumor tissues following xenografted mice CDPs treated. Notably, genes involved in EMT, invasiveness, and metastasis—including PTEN, SNAIL, CXCL1, BRCA1, GADD45A, and PD-L1—were dysregulated in the livers of animals with TNBC, but CDPs treatment restored them to healthy levels more effectively than MTX. Conclusions: The anti-metastatic effects of CDPs in the MDA-MB-231 line involve inhibiting phosphorylation of components of the Akt/mTOR/S6K pathway and reducing metastasis markers and proliferation regulators, as demonstrated in cultures of the MDA-MB-231 line and in tumor and liver tissues from the TNBC xenograft mouse model. The anti-metastatic activity of CDPs was more effective than MTX alone; however, combined treatment produced a synergistic effect, increasing efficacy. These findings offer new insights into the mechanism of action of CDPs and their potential as candidates for further preclinical development.